Prolonged XPO1 inhibition is essential for optimal antileukemic activity in NPM1-mutated AML.
Pianigiani G, Gagliardi A, Mezzasoma F, Rocchio F, Tini V, Bigerna B, Sportoletti P, Caruso S, Marra A, Peruzzi S, Petito E, Spinozzi G, Shacham S, Landesman Y, Quintarelli C, Gresele P, Locatelli F, Martelli MP, Falini B, Brunetti L.
Pianigiani G, et al. Among authors: petito e.
Blood Adv. 2022 Nov 22;6(22):5938-5949. doi: 10.1182/bloodadvances.2022007563.
Blood Adv. 2022.
PMID: 36037515
Free PMC article.